Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CFT7455 | Ligand for E3 Ligase | TargetMol
CFT7455 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
CFT7455 | Selleck Chemicals
CFT7455 | CAS:2504235-67-8 | AxisPharm
CFT7455 / C4 Therap
CFT7455 82010
CFT7455 | 2504235-67-8 | AbMole | Cemsidomide
CFT7455 - Multiple Myeloma Clinical Trials
C4的王牌：新一代的IMiD CFT7455 $C4 Therapeutics(CCCC)$ 在今天2021年4月10日的AACR年会上，C4 ...
FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma ...
CCCC | C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 ...
(Rac)-Cemsidomide ((Rac)-CFT7455) | IKZF1/IKZF3 Degrader | MedChemExpress
Cemsidomide (CFT7455) | IKZF1/3 degrader | Probechem Biochemicals
速递|多发性骨髓瘤新药:FDA授予CFT7455多发性骨髓瘤孤儿药称号_全球肿瘤医生网
PROTAC：CFT7455安全性堪忧、C4 Therapeutics股价腰斩 - 药时代DrugTimes
CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in ...
Summary of Molecular Glues Approved or in Clinical Trial.pdf
slide31
slide33
slide8
slide10
slide26
IKZF1/3分子胶安全性堪忧，C4 Therapeutics股价腰斩医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Ingo Hartung on Twitter: "James Henderson @C4Therapeutics disclosing ...
slide19
slide4
slide3
Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 ...
A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple ...
Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates ...
Initial Results of a Phase 1 First-in-Human Study of Cemsidomide ...
slide2
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 ...
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation ...
Abstract P39: CFT7455, a novel IKZF1/3 degrader enhances the anti ...
(CFT-7455)-药物靶点：IKZF1 + IKZF3_在研适应症：多发性骨髓瘤，非霍奇金淋巴瘤_专利_临床_研发
C4T, ‘IKZF1/3 TPD’ MM 1/2상 “실패, 독성이슈도" - 바이오스펙테이터
LOGO
slide7
slide29
slide13
slide32
slide28
slide35
slide14
slide34
cccc-20240111
slide5
slide9
slide17
CFT7455, 2504235-67-8 | BroadPharm
slide37
slide30
slide12
slide6
Cemsidomide Combo May Produce Responses in Multiple Myeloma
C4 Therapeutics的CFT7455获FDA孤儿药认定-奥来恩医药-中美双报_FDA IND/NDA/BLA_新药注册-奥来恩医药
slide16
CFT7455: A potential treatment for multiple myeloma | C4 Therapeutics ...
CFT7455的晶型物及其制造方法与流程
(S)-CFT7455 – Xcess Biosciences
Discovery and Characterization of Novel IKZF1/3 Glue Degraders against ...
CART-ddBCMA Gets FDA Orphan Drug Status for Multiple Myeloma
OR | Discovery and Characterization of Novel IKZF1/3 Glue Degraders ...
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells ...
CFT7455—2504235-67-8 品牌:魏氏试剂 湖北武汉 - ChemicalBook
OR | Free Full-Text | Discovery and Characterization of Novel IKZF1/3 ...
分子胶：CFT7455安全性堪忧、C4 Therapeutics股价腰斩 2022年4月8日， C4 Therapeutics 公布了其首发 ...
2504235-67-8_(S)-CFT7455CAS号:2504235-67-8/(S)-CFT7455中英文名/分子式/结构式 – 960化工网
Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging ...
Targeted Protein Degraders | PicoImmune Co.
C4 Therapeutics Reports Encouraging Results from Initial Study of ...
cccc-10k_20211231.htm
FDA授予CFT 7455治疗多发性骨髓瘤的孤儿药物名称-上市-医保-临床适应症-香港济民药业
C4 Therapeutics, Inc. on LinkedIn: We recently shared new preclinical ...
新型靶向药cemsidomide（CFT7455）在多发性骨髓瘤及非霍奇金淋巴瘤临床研究中展现潜力 - MedFind
C4 Therapeutics Inc.: C4 Therapeutics Announces Positive Data from ...
(Rac)-CFT7455 Price from Supplier Brand DC Chemicals Limited on Chemsrc.com
Full article: Microbial metabolite butyrate modulates granzyme B in ...
slide23
诺诚建华申报IKZF1/3分子胶新药 2022年4月29日， 诺诚健华 ICP-490片的临床试验申请获得NMPA受理。来那度胺、泊马度胺等 ...
Discovery and characterization of a selective IKZF2 glue degrader for ...
Molecular glues are beginning to stick
